HDAC9 and obesity due to melanocortin 4 receptor deficiency: Given the inhibitory effects of butyrate on HDAC9 and these important roles of HDAC9 in physiological processes and disease development, HDAC9 inhibition is emerging as a promising strategy to treat chronic diseases such as stroke, atherosclerotic cardiovascular disease [34], kidney fibrosis [47], depression [48], and obesity.